Alnylam RNAi IP Upheld in European Opposition Proceedings

Alnylam said that opponents to the patent included Merck subsidiary Sirna Therapeutics, Silence Therapeutics, Pfizer, and BASF.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.